| |
| |
| Exchange: |
American Stock Exchange |
| Security
Type: |
Common |
| Shares
Out: |
49,160,000 |
| Market
Cap: |
379.52(M) |
| Last
Volume: |
0 |
Avg
Vol: |
0 |
| 52
Week Range: |
$2.14 - $13.81 |
|
| Level
I Sector: |
Financials |
| Level
II Sector: |
Financial Services |
| Level
III Sector: |
Diversified Investments |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile Altimmune is a clinical stage biopharmaceutical company focused on developing treatments for obesity and liver diseases. Co.'s primary product candidate, pemvidutide (proposed INN), is a good laboratory practices-1/glucagon dual receptor agonist that is being developed for the treatment of obesity and non-alcoholic steatohepatitis. In addition, Co. is developing HepTcell, an immunotherapeutic agent designed to achieve a functional cure for chronic hepatitis B.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
300 |
31,500 |
| Total Buy Value |
$0 |
$0 |
$863 |
$138,033 |
| Total People Bought |
0 |
0 |
1 |
3 |
| Total Buy Transactions |
0 |
0 |
1 |
6 |
| Total Shares Sold |
0 |
0 |
0 |
155,302 |
| Total Sell Value |
$0 |
$0 |
$0 |
$2,133,902 |
| Total People Sold |
0 |
0 |
0 |
5 |
| Total Sell Transactions |
0 |
0 |
0 |
9 |
| End Date |
2024-02-08 |
2023-11-07 |
2023-05-09 |
2022-05-09 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Garg Vipin K |
President and CEO |
• • – |
2020-11-30 |
4 |
D |
$12.23 |
$27,432 |
D/D |
(2,243) |
317,501 |
|
- |
|
| Gill John |
Director |
– • – |
2020-11-30 |
4 |
AS |
$11.92 |
$100,426 |
D/D |
(8,425) |
11,199 |
|
3% |
|
| Drutz David |
Director |
– • – |
2020-11-13 |
4 |
OE |
$2.40 |
$144 |
D/D |
60 |
17,603 |
|
- |
|
| Harris Matthew Scott |
Director |
– • – |
2020-11-12 |
4 |
AS |
$10.02 |
$40,230 |
D/D |
(4,015) |
4,069 |
|
33% |
|
| Pisano Wayne |
Director |
– • – |
2020-11-12 |
4 |
AS |
$9.90 |
$102,485 |
D/D |
(10,352) |
8,498 |
|
33% |
|
| Schafer Klaus |
Director |
– • – |
2020-11-12 |
4 |
AS |
$9.91 |
$100,587 |
D/D |
(10,150) |
6,900 |
|
33% |
|
| Garg Vipin K |
President and CEO |
• • – |
2020-10-30 |
4 |
D |
$11.45 |
$23,072 |
D/D |
(2,015) |
319,744 |
|
- |
|
| Garg Vipin K |
President & CEO |
• • – |
2020-09-30 |
4 |
D |
$13.20 |
$26,598 |
D/D |
(2,015) |
321,759 |
|
- |
|
| Schafer Klaus |
Director |
– • – |
2020-09-24 |
4 |
OE |
$0.00 |
$0 |
D/D |
16,850 |
17,050 |
|
- |
|
| Sayare Mitchel |
Director |
– • – |
2020-09-24 |
4 |
OE |
$0.00 |
$0 |
D/D |
25,275 |
26,363 |
|
- |
|
| Drutz David |
Director |
– • – |
2020-09-24 |
4 |
OE |
$0.00 |
$0 |
D/D |
16,850 |
17,543 |
|
- |
|
| Pisano Wayne |
Director |
– • – |
2020-09-24 |
4 |
OE |
$0.00 |
$0 |
D/D |
16,850 |
18,850 |
|
- |
|
| Gill John |
Director |
– • – |
2020-09-24 |
4 |
OE |
$0.00 |
$0 |
D/D |
16,850 |
19,624 |
|
- |
|
| Hodges Philip |
Director |
– • – |
2020-09-24 |
4 |
OE |
$0.00 |
$0 |
D/D |
16,850 |
36,306 |
|
- |
|
| Garg Vipin K |
President & CEO |
• • – |
2020-08-30 |
4 |
D |
$17.62 |
$35,504 |
D/D |
(2,015) |
323,774 |
|
- |
|
| Garg Vipin K |
Chief Financial Officer |
• • – |
2020-07-31 |
4 |
A |
$1.46 |
$17,044 |
D/D |
11,674 |
325,789 |
|
- |
|
| Brown William Michael |
Chief Financial Officer |
• – – |
2020-07-31 |
4 |
A |
$1.46 |
$11,563 |
D/D |
7,920 |
15,981 |
|
- |
|
| Harris Matthew Scott |
Chief Medical Officer |
• – – |
2020-07-31 |
4 |
A |
$1.46 |
$11,803 |
D/D |
8,084 |
8,084 |
|
- |
|
| Roberts M Scot |
Chief Scientific Officer |
• – – |
2020-07-31 |
4 |
A |
$1.46 |
$5,634 |
D/D |
3,859 |
9,394 |
|
- |
|
| Garg Vipin K |
President and CEO |
• • – |
2020-07-30 |
4 |
D |
$26.06 |
$52,511 |
D/D |
(2,015) |
314,115 |
|
- |
|
| Garg Vipin K |
President and CEO |
• • – |
2020-06-30 |
4 |
D |
$10.71 |
$21,581 |
D/D |
(2,015) |
316,130 |
|
- |
|
| Shah Nimish P |
10% Owner |
– – • |
2020-06-15 |
4 |
B |
$7.54 |
$11,310,000 |
I/I |
1,500,000 |
4,500,000 |
1.5 |
54% |
|
| Garg Vipin K |
President and CEO |
• • – |
2020-05-30 |
4 |
D |
$9.28 |
$18,699 |
D/D |
(2,015) |
318,145 |
|
- |
|
| Shah Nimish P |
10% Owner |
– – • |
2020-05-28 |
4 |
B |
$7.79 |
$1,757,090 |
I/I |
201,474 |
3,000,000 |
1.5 |
58% |
|
| Shah Nimish P |
10% Owner |
– – • |
2020-05-27 |
4 |
B |
$7.23 |
$3,098,761 |
I/I |
402,162 |
2,798,526 |
1.5 |
64% |
|
417 Records found
|
|
Page 6 of 17 |
|
|
| |
Transaction Code Key: |
Ownership Code Key |
| |
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
| |
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
| |
OE |
- Options Exercised |
A |
- Acquired |
| |
IO |
- Initital Ownership |
D |
- Disposed |
| |
|
|
|
|
|
0.56 (7.82%) 
